Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s short- to medium-term momentum and raising concerns about its near-term price trajectory.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators present a complex picture, with bearish signals dominating weekly charts while monthly indicators offer a more nuanced outlook. This article analyses the latest price momentum, key technical indicators, and the implications for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish trend to a sideways movement. Despite a recent downgrade in daily price performance, the stock’s monthly indicators suggest underlying strength, presenting a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance despite a recent 4.58% decline in its share price. The company’s technical indicators present a complex picture, with weekly and monthly signals diverging across key metrics such as MACD, RSI, Bollinger Bands, and moving averages. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term prospects.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 22 April 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflected in a downgrade of its Mojo Grade from Sell to Hold as of 17 July 2025. Despite a recent day decline of 3.74%, the stock’s technical indicators present a complex picture with contrasting signals across weekly and monthly timeframes, suggesting a sideways trend after a period of mild bullishness.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and technical parameter changes suggest cautious optimism for investors in this micro-cap pharmaceutical player.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a sideways movement. Despite a strong one-week return outperforming the Sensex, the stock’s medium-term outlook remains cautious amid mixed signals from MACD, RSI, and moving averages.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 February 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.